3200 new patients a year in the UK would be a ceiling of newly diagnosed patients, yes. As I recall, the e manufacturing capacity at this time was something like 1000 patients, making it a moot point anyway, right?
I did not say the company’s value “will” go down after approval, only that it would not be a surprise to me if NWBO follows the pattern of other cell therapy companies who did fall after approval. Skyrocketing share price is far far from a guarantee, especially if we assume DCVax approval is a lock (and therefore not a surprise)
Market Data 
Markets 
AI
